secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001683168-24-006318
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma regains Nasdaq compliance; subject to one-year Mandatory Panel Monitor
--------------------------------------------------------------------------------

- On Sep 10, 2024, Nasdaq confirmed CNS Pharma has demonstrated compliance with the $2.5M stockholders' equity requirement; delisting matter closed.
- Company is subject to a Mandatory Panel Monitor for one year; if non-compliance recurs, immediate delist with no cure period.
- Previous extensions from Aug 2023 to Aug 2024 to regain compliance; now resolved with heightened monitoring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824006318/0001683168-24-006318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824006318/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-006318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer